Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr Agarwal’s Health CareBOM:544350 +0.12%17 EBITDA Margin % is 31.09% as of Mar. 2026, which is 7% above its 10-year median of 29.19. GuruFocus rates BOM:544350 with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Dr Agarwal’s Health Care ranks better than 89.94% on this metric.
Dr Agarwal’s Health Care (BOM:544350) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dr Agarwal’s Health Care EBITDA Margin % Related Terms
Dr Agarwal’s Health Care EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544350 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Dr Agarwal’s Health Care's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Agarwal’s Health Care EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dr Agarwal’s Health Care's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dr Agarwal’s Health Care's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Agarwal’s Health Care (BOM:544350) has a EBITDA Margin % of 31.09% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr Agarwal’s Health Care and its competitors. This is near median its historical median of 29.19. Over the past decade, Dr Agarwal’s Health Care's EBITDA Margin % has ranged from 27.93 to 30.62. According to the industry distribution chart, Dr Agarwal’s Health Care ranks #82 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 10.1%.
Is Dr Agarwal’s Health Care's EBITDA Margin % too high?
Dr Agarwal’s Health Care's current EBITDA Margin % of 31.09% is near median its 10-year median of 29.19. Over the past 10 years, this metric has ranged from a low of 27.93 to a high of 30.62. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Dr Agarwal’s Health Care's value of 31.09% is 313.4% above this industry median. Based on the distribution chart, Dr Agarwal’s Health Care ranks #82 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Dr Agarwal’s Health Care has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Dr Agarwal’s Health Care's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Dr Agarwal’s Health Care ranks #82 out of 815 companies for EBITDA Margin %. This places Dr Agarwal’s Health Care in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.52. Dr Agarwal’s Health Care's value of 31.09% is 313.4% above this benchmark. Historically, Dr Agarwal’s Health Care's own EBITDA Margin % has ranged from 27.93 to 30.62 over the past decade. While the company's 10-year median is 29.19 vs. the industry median of 7.52, Dr Agarwal’s Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr Agarwal’s Health Care's current EBITDA Margin % of 31.09% is 313.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr Agarwal’s Health Care and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Agarwal’s Health Care's current EBITDA Margin % is 31.09%, which is near median its own 10-year median of 29.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Agarwal’s Health Care stock overvalued right now?
Dr Agarwal’s Health Care (BOM:544350) has a current EBITDA Margin % of 31.09%. The current EBITDA Margin % is 31.09%, which is near median its 10-year median of 29.19 and 313.4% above the Medical Devices & Instruments industry median of 7.52. Dr Agarwal’s Health Care's overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dr Agarwal’s Health Care (BOM:544350), the current EBITDA Margin % is 31.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dr Agarwal's Health Care Ltd is engaged in eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lenses and accessories, and eye care related pharmaceutical products. It offer services such as Surgeries, Cataract surgeries, Refractive surgeries, Other surgeries, and Consultations, diagnoses and non-surgical treatments, Its products services include Sale of opticals and Sale of eye care-related pharmaceutical products. The company is engaged in single segment that is eye care and related services provided from its hospitals which are located in India and Africa. It generates maximum revenue from India.
17GF Score
Get the complete analysis for BOM:544350
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544350 has been successfully added to your 
